Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan and Fulvestrant in GATA3-mutant Advanced Breast Cancer
NCT05932667Phase 2Terminated
- Sponsor
- Institut Curie
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of milademetan in breast cancer, sponsored by Institut Curie. Started Oct 2023; status: terminated.
02
Drugs
milademetan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05932667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932667.